Q-omics provides the consensus-scored SFTPC profile across patient tissues and cancer cell-line models. SFTPC expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SFTPC is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SFTPC RNA expression shows 15,153 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, THCA, and LSCC as cancer lineages where SFTPC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTPC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTPC survival associations across molecular data types. SFTPC RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTPC RNA expression–survival associations across cancer types. High SFTPC expression shows unfavorable associations in UCEC, ACC, CHOL, BLCA and LUSC, but favorable associations in LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SFTPC RNA expression.
This table summarizes SFTPC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SFTPC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTPC shows lower tumor expression in THCA, LUSC, LUAD and PRAD and higher tumor expression in PAAD and LIHC. The THCA box plot shows higher SFTPC RNA expression in normal versus tumor tissue (log2 FC = −2.170, t-test p < 0.001).
This table shows molecular features associated with SFTPC in patient tissues and cancer cell lines. In patient samples, SFTPC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFTPC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
